Drug interactions
Encorafenib + Liposomal doxorubicin
Severity: Minor
Encorafenib and Liposomal doxorubicin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib both inhibits and induces CYP3A4, so effects on doxorubicin exposure are unpredictable. Since CYP3A4 is a minor route for doxorubicin, the net effect is likely small.
What this interaction means in plain words
Encorafenib and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Encorafenib belongs to Oncology; Liposomal doxorubicin belongs to Oncology.
Why it happens
Mixed CYP3A4 inhibition and induction by encorafenib may alter doxorubicin metabolism.
What to do
No empiric dose change; monitor efficacy and toxicity of doxorubicin, including cardiac function.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Liposomal doxorubicin?
MediHelp rates the interaction as minor. Encorafenib and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Encorafenib both inhibits and induces CYP3A4, so effects on doxorubicin exposure are unpredictable. Since CYP3A4 is a minor route for doxorubicin, the net effect is likely small.
How serious is the interaction between Encorafenib and Liposomal doxorubicin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empiric dose change; monitor efficacy and toxicity of doxorubicin, including cardiac function.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
